-
Exploring New Breast Cancer Risk Genes, Biomarkers, and Prognostic Models at AACR 2023
The American Association for Cancer Research (AACR) held its annual conference from April 14th to 19th, 2023 in Orlando, USA. With numerous reports on clinical, fundamental, and translational cancer research presented each year, this year’s AACR conference delved deep into the realm of breast cancer. Research focused on the analysis of various susceptibility genes and…
-
New Data on KRAS G12C Inhibitor in the Treatment of Advanced Non-Small Cell Lung Cancer
The 2023 annual meeting of the American Association for Cancer Research (AACR) was held in Orlando, USA, from April 14th to 19th, 2023. Various important basic and clinical research results were presented at the conference, including the latest results of a Phase I study of IBI351 monotherapy in patients with advanced solid tumors from China.…
-
Progress of ctDNA in predicting prognosis of patients with urological tumors
Circulating tumor DNA (ctDNA) for predicting tumor prognosis and guiding individualized treatment is a hot topic in malignant tumor research. ctDNA exists in the peripheral blood of tumor patients in a cell-free state and can dynamically evaluate the tumor condition, overcoming tumor heterogeneity biases. The 2023 American Association for Cancer Research (AACR) Annual Meeting was…
-
KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract Cancer Patients
According to the KEYNOTE-966 study results announced at the 2023 American Association for Cancer Research (AACR) annual meeting, adding pembrolizumab on the basis of gemcitabine and cisplatin brings statistically and clinically significant survival benefits to patients with advanced biliary tract cancer. These results validate the outcomes of the randomized phase III TOPAZ-1 study. Encouragingly, this…
-
Innovative Chinese Immunotherapy, Sintilimab Sets New Survival Records for Upper Gastrointestinal Cancers
At the 2023 American Association for Cancer Research (AACR) annual meeting held on April 17, groundbreaking long-term follow-up data from studies on the Chinese innovative PD-1 inhibitor, Sintilimab, was unveiled. The findings span from phase III clinical trials for esophageal cancer (ORIENT-15) and gastric cancer (ORIENT-16). The results from these trials have set new longevity…
-
IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence
Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high…
-
Prostate Cancer Radiation Therapy Research: SBRT vs Surgery; Conventional Radiation vs Large Fraction Radiation
The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of prostate cancer radiation therapy, two phase 3 clinical studies were selected for oral presentation: The PACE-A study explores stereotactic body radiation therapy (SBRT) compared to surgery for localized prostate cancer;…
-
Key Insights from the 2023 ASCO-GU Conference on Sacituzumab Govitecan in Advanced Urothelial Cancer
Advanced urothelial cancer (aUC) has seen remarkable progress in recent years with the emergence of antibody-drug conjugates (ADCs) targeting specific antigens. Trop-2, a cell surface antigen highly expressed in UC, has become a promising therapeutic target. Sacituzumab govitecan (SG), a next-generation Trop-2 ADC, received accelerated approval from the US FDA in April 2021 for treating…
Connecting Medical Expertise through Media